StockNews.com Initiates Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Stock analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their target price on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Price Performance

NASDAQ APVO opened at $0.28 on Friday. The business has a fifty day moving average price of $0.23 and a 200 day moving average price of $0.39. Aptevo Therapeutics has a one year low of $0.14 and a one year high of $10.80.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.